Drug gives lung cancer patients four extra months
Most lung cancer patients survived four months longer on an immunotherapy drug than those treated with chemotherapy, according to trial results published Monday.

Importantly, they also experienced fewer side-effects, researchers reported in The Lancet medical journal.

Patients with non-small-cell lung cancer -- which represents by far the majority -- survived for 13.8 months on average on the drug called atezolizumab, compared to 9.6 months for those on chemotherapy, the study authors said.

And the difference was likely even bigger, as several participants on chemotherapy were given immunotherapy after the trial ended, possibly boosting their survival...

http://zeenews.india.com/health/drug-gives-lung-cancer-patients-four-extra-months-1957903
Like
Comment
Share